TY - JOUR
T1 - Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
T2 - A Systematic Review
AU - Kallini, Joseph Ralph
AU - Gabr, Ahmed
AU - Thorlund, Kristian
AU - Balijepalli, Chakrapani
AU - Ayres, Dieter
AU - Kanters, Steve
AU - Ebrahim, Shanil
AU - Mills, Edward
AU - Lewandowski, Robert J.
AU - Salem, Riad
N1 - Funding Information:
The data analysis supporting this manuscript was developed by Redwood Outcomes Inc. and was supported by funding from BTG International Inc.
Publisher Copyright:
© 2017, Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
PY - 2017/7/1
Y1 - 2017/7/1
N2 - To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere® and SIR-Spheres®, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.
AB - To compare the safety profiles of TheraSphere® (glass) and SIR-Spheres® (resin) Y90 microspheres for the treatment of hepatocellular carcinoma. A systematic review was conducted using the databases MEDLINE, Embase, and Cochrane Trials Register to identify all relevant studies. Baseline characteristics and adverse events of all grades related to gastrointestinal, hepatobiliary, and respiratory systems were collected along with commonly reported outcomes related to post-embolization syndrome. For all outcomes, data from each study were tabulated for each intervention. Adverse events and patients were summed across studies on TheraSphere® and SIR-Spheres®, respectively, and the resulting proportion of patients experiencing an outcome for both interventions was calculated. Thirty-one observational studies were included in the review. In the adverse events of all grades, more patients treated with resin microspheres reported gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, and pleural effusion. Patients treated with resin microspheres also had more hepatobiliary adverse events of grade 3 or higher. In the events related to post-embolization syndrome, glass microspheres exhibited a similar safety profile compared to resin microspheres. Ascites and nausea grade 3 or higher were recorded more frequently with glass microsphere treatment. Based on this review of the published literature, glass microspheres exhibit a safety profile with fewer gastrointestinal and pulmonary adverse events compared to resin microspheres in the treatment of hepatocellular carcinoma.
KW - Adverse event
KW - HCC
KW - Hepatocellular carcinoma
KW - SIR-Spheres
KW - Safety
KW - TheraSphere
KW - Y90
KW - Yttrium-90
UR - http://www.scopus.com/inward/record.url?scp=85014015731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014015731&partnerID=8YFLogxK
U2 - 10.1007/s00270-017-1594-4
DO - 10.1007/s00270-017-1594-4
M3 - Article
C2 - 28246879
AN - SCOPUS:85014015731
SN - 7415-5101
VL - 40
SP - 1033
EP - 1043
JO - Cardiovascular Radiology
JF - Cardiovascular Radiology
IS - 7
ER -